Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hyatt Regency Bethesda

Oct 07, 2015 7:00 AM - Oct 07, 2015 4:30 PM

One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814-5326

Achieving Meaningful Regulatory and Clinical Outcomes for Patients: Strategies in Rare Disease Therapy Development

A collaborative workshop designed to examine practical issues in the structuring of rare diseases therapeutic development programs.

Overview

Travel Once, Learn Twice and Save
Save when you register for both the Achieving Meaningful Regulatory and Clinical Outcomes for Patients: Strategies in Rare Disease Therapy Development and the Advancing the Science of Study Endpoints: Seeking Practical Solutions
*You must register for both events at the same time.  Details in the Registration section listed on the left.


Patient Organizations/Patients are invited to attend the Achieving Meaningful Regulatory and Clinical Outcomes for Patients: Strategies in Rare Disease Therapy Development at a reduced registration fee of $200. 

Questions? Contact:

Send Email
1.215.442.6158

Download registration form

Tutorial:  October 6*
Workshop Date:  October 7

*Tutorials require registration and are an additional fee


This is a one-day, intensive workshop on structuring rare disease therapeutic development programs that integrate patient, regulatory, and clinical perspectives to achieve the most meaningful outcomes for patients.  Knowledge will be shared on establishing the foundation of a cohesive regulatory framework for rare disease therapeutic development through scientific planning.  Workshop participants will examine the unique aspects of clinical endpoint and study design for rare disease therapies, and how engagement of patient organizations and regulators can facilitate the development of a program.  A case study on the development of a “mock” therapy will allow participants to explore practical issues in the development of the clinical program and in the integration of the patient and regulatory perspectives into a comprehensive strategy to meet patient needs.

Featured topics

  • Rare Disease Protocol Development
  • Addressing the Challenges of Early Patient Engagement
  • Making the Most of What FDA Offers
  • Regulatory Challenges of Orphan Drug Development

Featured

Want to learn more about Achieving Meaningful Regulatory and Clinical Outcomes for Patients: Strategies in Rare Disease Therapy Development? You've come to the right site!

Continuing-Education

Exhibits

Who should attend?

  • Researchers from academia and drug and device companies
  • Senior managers from drug and device companies interested in rare diseases
  • Regulatory affairs professionals working with rare disease therapies and orphan products
  • Professionals involved in clinical trial design for rare disease therapies
  • Professionals involved in setting, executing, or evaluating endpoint strategies
  • Government officials responsible for rare disease research and orphan product oversight
  • Investors focused on the future of orphan product development
  • Patient organizations and those interested in creating one

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain how patient engagement can be successfully interwoven in regulatory and clinical programs
  • Describe at least two resources at FDA that can be leveraged to assist companies developing rare disease therapies
  • Discuss special considerations for study endpoint identification and development for rare disease therapies
  • Discuss the differences in working with FDA on the development of rare disease therapies as compared to therapies for more common diseases
  • Discuss the importance of collaboration between key stakeholders in the development of rare disease therapies
  • Recognize issues related to the clinical development of new therapies for rare disease populations

Short Course or Primer

To keep you at the forefront.

Oct 06, 2015

Tutorial:

Study Endpoint Development in Rare Diseases

Program Committee

  • David H. Schubert
    David H. Schubert
    DH Schubert Regulatory Solutions LLC, United States
  • Jessica E. Foley
    Jessica E. Foley Principal & Founder
    Gaia Regulatory Sciences, United States
  • Shaghig  Palanjian, MBA
    Shaghig Palanjian, MBA Vice President, Global Head, R&D QA and Compliance
    Shire, United States
  • Steven L. Roberds, PhD
    Steven L. Roberds, PhD Chief Scientific Officer
    Tuberous Sclerosis Alliance, United States
  • Scott  Schliebner, MPH
    Scott Schliebner, MPH Senior Vice President, Clinical Development Services
    TFS Health Science, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.